ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.

Raccontata dafiercepharma.combiopharmadive.comfiercebiotech.comstatnews.commorningstar.comscmp.comthenextweb.com